Alex Blyth, Founder and CEO of LIfT BioSciences, discusses the groundbreaking developments in #neutrophil #celltherapies aimed at revolutionizing #cancer treatment in this exclusive interview for #ONCOLife. With a focus on Immunomodulatory Alpha Neutrophils, Alex Blyth, explains their unique ability to recruit and modulate the #immune system, enhancing the effectiveness of existing #cancertherapies such as bi-specifics, #ADC’s, checkpoint inhibitors and #CARTcellTherapy. #Oncology https://lnkd.in/dE4d_Cvx
Health and Pharma
Internet News
New York, New York State 2,193 followers
Health & Pharma is a global news platform on life sciences, biotech, drug discovery, and pharmaceutical industry events
About us
Health and Pharma is a global news platform on life sciences, biotech, drug discovery, and pharmaceutical industry events. We strive to be a trusted news outlet, delivering firsthand reports from reliable channels. Our goal is to collaborate with health science and pharma professionals.
- Website
-
https://healthandpharma.net/
External link for Health and Pharma
- Industry
- Internet News
- Company size
- 2-10 employees
- Headquarters
- New York, New York State
- Type
- Privately Held
Locations
-
Primary
Get directions
New York, New York State 10027, US
Employees at Health and Pharma
Updates
-
Southern #Sweden is a sweet spot for #lifesciences and we are delighted to be attending Nordic Life Science Days there in Malmö this September. The region enjoys outstanding local support from SwedenBIO & Medicon Valley Alliance. Read all about this powerful European #biotech & #medtech #science cluster in our latest #marketing feature: https://lnkd.in/eiR9QVNG Katja Stout & Daniel Gooch are excited to meet new and existing clients to support their #communications needs. Don’t delay, register today, and save up to EUR 300 on the largest life science partnering conference in the Nordics: https://lnkd.in/d5TT8sX #NLSDays #pharma #networking #investors #greatplacetowork
Why Southern Sweden is Sweet for Science - NLSDays
https://www.nlsdays.com
-
#FDA has approved #Zymeworks' investigational drug, #ZW171, for clinical trials. This novel #bispecific #antibody targets mesothelin-expressing cancers, such as ovarian #cancer and non-small cell #lungcancer. ZW171 represents a new class of cancer therapy known as 2+1 T-cell targeting bispecific antibodies. These are engineered to boost the body’s immune response against #cancercells without harming healthy tissues. https://lnkd.in/d9SM2QbP
-
-
Grifols announced that the #FDA has granted approval to #Yimmugo®, for primary #immunodeficiency. Developed by Biotest AG, Yimmugo® is an intravenous #immunoglobulin (IVIg) used for substitution therapy in patients with primary #antibody deficiency syndromes, where parts of the body's #immune system are either missing or function improperly. #antibodydeficiency https://lnkd.in/dGm38f2y
FDA Approves Grifols' Yimmugo® for Primary Immunodeficiency, Marking a Milestone
healthandpharma.net
-
Foundation founder and chairman Neal F. Kassell, MD, was recently interviewed for an article in ONCOLife Health and Pharma about the potential of focused ultrasound to transform the treatment of brain cancers. Dr. Kassell discusses how this rapidly evolving, noninvasive technology enhances drug delivery by opening the blood-brain barrier, enabling targeted therapy with reduced systemic toxicity. Read the full interview: https://lnkd.in/dEPMX98b
-
-
Bristol Myers Squibb presented positive results from the #CheckMate-9DW trial at the #ASCO24 annual meeting, showing that the #Opdivo-#Yervoy therapy could become the first-line treatment for #hepatocellular #carcinoma. This dual #immunotherapy combination extended median survival to 23.7 months —a 21% improvement in survival risk— and notably increased the objective response rate to 36% from 13%. https://lnkd.in/dW7DBg3T
ASCO24: Opdivo Plus Yervoy Significantly Improves Overall Survival for Liver Cancer Patients
healthandpharma.net
-
AbbVie revealed compelling new data at the #ASCO24 Annual Meeting, from its innovative antibody-drug conjugate platform, showcasing potential breakthroughs in the treatment of several difficult-to-treat cancers. https://lnkd.in/e4JAWq5n
AbbVie presented promising new data at #ASCO24 for its innovative #antibody-drug conjugates (#ADCs) targeting Solid #Tumors. Highlights include efficacy of #ABBV400 in metastatic #colorectal #cancer, ABBV-706 in small cell #lungcancer and #neuroendocrine tumors, and #TelisoV in non-small cell lung cancer. These ADCs target specific #biomarkers, offering hope for difficult-to-treat tumors. "Our ADC platform allows us to utilize selected biomarkers such as c-Met and SEZ6 to induce targeted cancer cell death by delivering potent anti-cancer agents. The data we are presenting at ASCO demonstrate the clinical potential of this approach across a wide range of difficult-to-treat tumors," said Dr. Oyewale Daejin Abidoye Abidoye, M.D., V.P. Head of Solid Tumors, #Oncology Development, AbbVie. https://lnkd.in/eBJAfGx3
AbbVie Reveals Promising ADC Data for Advanced Cancer Treatments at ASCO 2024
healthandpharma.net
-
Susan Galbraith, Executive Vice President of #Oncology R&D at AstraZeneca, highlighted the significant advances and stated, “Tagrisso extended progression-free survival by more than three years in this potentially curative setting, reinforcing the need to test and diagnose patients early. These practice-changing data cement the powerful impact #Tagrisso can make as backbone therapy in EGFR-mutated #lungcancer, especially in the lives of these patients who have historically experienced early progression following #chemoradiotherapy.” https://lnkd.in/eh-m5BvF
AstraZeneca announced that its drug #Tagrisso (#osimertinib) has significantly improved outcomes for patients with unresectable, Stage III #EGFR-mutated non-small cell #lungcancer in the LAURA Phase III trial. Results presented at the #ASCO24 meeting showed that Tagrisso reduced the risk of disease progression or death by 84% compared to placebo, offering a potential new standard of care. #cancer https://lnkd.in/ermdgiWm
ASCO 2024: Tagrisso Extends Survival in Stage III EGFR-Mutated Lung Cancer Treatment
healthandpharma.net
-
GenFleet Therapeutics announced encouraging results from the Phase II #KROCUS study at the #ASCO24 meeting, showcasing the efficacy of combining #fulzerasib with #cetuximab in treating non-small cell #lungcancer (#NSCLC). The study highlighted an 81.8% objective response rate and a strong safety profile, marking a significant advancement in first-line treatment options for #lung #cancer patients with the #KRASG12C mutation. The data, presented by Dr. Vanesa Gregorc, highlighted that this combination therapy demonstrated promising efficacy and a good safety profile. https://lnkd.in/dpcG_jVp
GenFleet's Fulzerasib Combo Achieves 81.8% Response Rate in First-Line Lung Cancer Treatment
healthandpharma.net
-
Novartis' #Scemblix® has shown superior efficacy and safety in treating newly diagnosed chronic #myeloidleukemia (#CML) compared to standard TKIs in a Phase III trial. The findings, presented at the 2024 American Society of Clinical #Oncology (#ASCO24) meeting, reveal that Scemblix (#asciminib) outperformed standard-of-care in newly diagnosed patients. https://lnkd.in/d5JCQkbb
#ASCO24: Scemblix® Outperforms Standard Treatments in Phase III Chronic Myeloid Leukemia Trial
healthandpharma.net